Amneal Will Go After 505(b)(2) Opportunity Under Patels’ Leadership

 
• By Aidan Fry

Capitalizing on opportunities in the US hybrid 505(b)(2) market will be central to Amneal’s strategy to revive its fortunes now its founders, brothers Chirag and Chintu Patel, have again taken the helm.

Hybrid
Hybrid 505(b)(2) drugs are a key part of Amneal's plans to revive its fortunes under new management • Source: Shutterstock

More from Value Added Medicines

More from Products